Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dalton Pharma Services
Dalton Pharma Services
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Tetra Bio-Pharma engages Dalton Pharma for GMP manufacturing
Tetra Bio-Pharma has awarded the contract for the manufacturing of its active pharmaceutical ingredient ARDS-003
Manufacturing
Dalton expands sterile fill/finish capabilities
The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion
Manufacturing
Dalton Pharma Services completes $5 million expansion
The project was supported by CA$2.085 million of funding from FedDev Ontario
Manufacturing
Lonza and Dalton to provide integrated chemistry services
Dalton adds geographic diversification to Lonza facilities network
Dalton's GMP oligonucleotide facility ready to roll
<p>Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.</p>
Subscribe now